Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 10 Health Care VC (Venture Capital) Funds in Latvia in November 2024

Last updated: Nov 2024 A list of 10 VC (Venture Capital) funds that invest in Health care startups based in Latvia. We rank investors based on the number of investments they made in Health care companies from Latvia. We update this investor list every month.

Top 10 Health Care VC (Venture Capital) Funds in Latvia in November 2024

Investor	Health Care Latvia investments
FlyCap	3
Abingworth	2
Qiming Venture Partners USA	2
SOSV	2
ZGI Capital	2
TSVC	1
Roche Venture Fund	1
Alexandria Venture Investments	1
Citadel	1
Surveyor Capital	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

FlyCap AIF is a Venture Capital Fund of total size of 15.75 MEUR. The Fund provides growth capital for Latvia based SME’s in a form of investments in equity and mezzanine capital.

Investment focus

Health Care, Consumer Goods, Medical
Funding Round, Seed, Debt Financing
Latvia, Estonia, The Netherlands

Portfolio highlights

Tapcore — Tapcore is the only solution on the market that enables mobile developers to monetize pirated copies of their apps through advertising. Established in 2015, we are a remote company with headquarters in the Netherlands. Currently we serve over 150 million ad requests daily (and counting!).
Purified — Purified is a nutritional supplement supplier.. It offers black chocolate produced by the best doctors in collaboration with scientists.
Elmo — In our car sharing business Elmo Rent we wanted to serve maximum customers with minimum resources, so we created remote control technology to deliver vehicles.

We are Abingworth, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, United Kingdom, France

Portfolio highlights

Q32 Bio — Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.
Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.

Qiming Venture Partners invests in young, fast-growing companies across China in the media and internet, IT, consumer and retail, healthcare, and clean technology sectors. we are early to growth stage venture capital firm with offices in Shanghai, Beijing and Hong Kong. Since their debut in 2006, we have established their selves as a leadinginvestment firm in China and currently manage four funds with over $1 billion in assets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Seed
United States, China, Canada

Portfolio highlights

Tourmaline Bio — Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases.
Jasper Therapeutics — Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant.
Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ZGI Capital is the fund management company that manages "ZGI fund”, that was founded to support entrepreneurs lacking start-up capital for their business. The total amount of assets available for venture capital investments is of EUR 7.4M. Combined with bank financing, this will allow to finance investment projects with total assets of up toEUR 30M. The fund acts on behalf of various investors including the State.

Investment focus

Manufacturing, Machinery Manufacturing, Consulting
Funding Round, Seed, Debt Financing
Latvia, Estonia

Portfolio highlights

eAgronom — eAgronom helps farmers generate additional revenue streams, improve soil quality, and access better financing.
KOOL Latvija — "KOOL Latvija" is a new concept gas station created in Latvia, which at the same time is also a convenient fast shopping place.
Bioreactors.net — Biotechnical center is an innovative company and we provide solutions for industrial biotechnology processes, bioreactor manufacturing and industrial automation. We manufacture bioreactors for laboratory, pilot and industrial scale.

Founded in 2010, TSVC (formerly TEEC Angel Fund) is proud to be a leading early-stage venture capital fund in Silicon Valley.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Funding Round, Series A
United States, China, Canada

Portfolio highlights

MyShell — The first AI consumer layer - build, share, and own AI Apps.
eBots — EBots is a collaborative robotics startup devoted to the development and manufacturing of intelligent robotics for industrial applications. They develop autonomous robotics designed for use in industrial applications and their platform combines machine learning with physical models, enabling users to realize intuitive human-machine interface,dexterous manipulation, and precise assembly. The company's platform combines machine learning with physical models, enabling users to realize an intuitive-human machine interface, dexterous manipulation, and precise assembly.EBots was founded in 2016 and is based in Fremont, CA, USA.
Ridge Security — Ridge Security is a computer and network services company that offers web app and server testing, and network infrastructure solutions.

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. Roche has been investing in early stage companies as part of collaborations since the early-1990s and independent ofcollaborations since 2002. All equity investments made by Roche in biotech and diagnostics companies (including collaboration investments) are negotiated and managed by the Roche Venture Fund. In the past 20 years, the Roche Venture Fund has invested in over 60 companies globally. Currently, Roche Venture Fund has a portfolio of around 30 companies located in 10 countries across Europe, North America and the Pacific Region. The fund is an evergreen fund with CHF 500 million available of which approximately 40% is currently invested.The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved in their fund for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. We co-invest with leading venture funds, including other corporate venture funds, on a regular basis.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team Latest News See more Our Work OUR APPROACH ABOUT DIABETES
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, France, Canada

Portfolio highlights

Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.

We are an alternative investment manager working on behalf of the world's preeminent institutions. Discover our work, teams, careers and more.

Investment focus

Biotechnology, Information Technology, Health Care
Series A, Series C, Seed
United States, India, Latvia

Portfolio highlights

Quant — Quant is a premier quantitative research and investment fund led by engineering, mathematics, and business students at the University of Illinois Urbana-Champaign. We employ state-of-the-art analysis tools like deep learning and natural language processing to gain an edge on financial markets across the globe.
Yellowbrick Data — Yellowbrick is a SQL data platform built on Kubernetes for enterprise data warehousing, ad-hoc and streaming analytics, AI and BI workloads. Yellowbrick offers unparalleled speed and scalability with minimal infrastructure, deployable across public and private clouds, data centers, laptops and the edge; providing a private data cloud experience that ensures data stays under your control to meet residency and sovereignty needs.
Texas Stock Exchange — The Texas Stock Exchange will focus on enabling U.S. and global companies to access U.S. equity capital markets and will provide a venue to trade and list public companies and the growing universe of exchange-traded products. TXSE will be a fully electronic, national securities exchange that will seek registration with the U.S. Securities and Exchange Commission.

Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Post-IPO Equity, Series C
United States, China, Switzerland

Portfolio highlights

Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Scorpion Therapeutics — We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.
BridgeBio Oncology Therapeutics — CinDome Pharma, a CinRx portfolio company, is advancing deudomperidone (CIN-102) for the treatment of chronic gastroparesis.

Investors by industry